Related Experiment Video
Updated: May 27, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Novel antiplatelet therapies.
Luke Kim1, Konstantinos Charitakis, Rajesh V Swaminathan
1Greenberg Division of Cardiology, New York Presbyterian Hospital, Weill Cornell Medical College, 520 East 70th Street, Starr-434 Pavilion, New York, NY 10021, USA.
Current Atherosclerosis Reports
|November 22, 2011
Summary
New antiplatelet drugs offer improved outcomes for ischemic heart disease patients. While prasugrel and ticagrelor show promise, ongoing research explores various agents to optimize therapy and minimize bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Antiplatelet therapy is crucial for managing ischemic heart disease.
- Thienopyridines (e.g., clopidogrel) are standard treatments but have limitations.
- Interpatient variability in clopidogrel response necessitates exploring alternatives.
Purpose of the Study:
- To review the evolving landscape of antiplatelet pharmacotherapy for ischemic heart disease.
- To compare the efficacy and safety profiles of existing and novel antiplatelet agents.
- To highlight areas for future research in antiplatelet drug development.
Main Methods:
- Literature review of clinical trials and pharmacological studies.
- Comparative analysis of pharmacokinetic and pharmacodynamic properties of antiplatelet drugs.
- Discussion of clinical outcomes and safety data from recent investigations.
Main Results:
- Prasugrel offers improved platelet inhibition but carries a higher bleeding risk.
- Ticagrelor demonstrates enhanced efficacy in recent trials, warranting further study.
- Variability in clopidogrel response underscores the need for personalized antiplatelet strategies.
Conclusions:
- The development of novel antiplatelet agents is rapidly advancing.
- Balancing efficacy and bleeding risk remains a key challenge in antiplatelet therapy.
- Further research is essential to optimize antiplatelet pharmacotherapy for ischemic heart disease.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...